Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 9/20 | 0.53 |
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.53 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.48 |
| ▸ | RELA | Q04206 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427793 | 0.86 | NPC1 (0.68) | ADORA3ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL18029557 | 0.86 | NPC1 (0.68) | ADORA3ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL14742257 | 0.81 | RAB9A (0.69) | NPC1RAB9ASMN1; SMN2TP53TDP1 | |
| SCHEMBL12297753 | 0.78 | MEN1 (0.69) | NPC1RAB9ASMN1; SMN2TP53TDP1 | |
| SCHEMBL5880712 | 0.78 | ADORA3 (0.68) | ADORA3ADORA2AADORA1CYP1A2MAPK1 | |
| SCHEMBL28911583 | 0.76 | MEN1 (0.59) | SMN1; SMN2CYP1A1CYP1A2CYP1B1MEN1 | |
| SCHEMBL30118286 | 0.76 | MEN1 (0.59) | SMN1; SMN2CYP1A1CYP1A2CYP1B1MEN1 | |
| SCHEMBL23539902 | 0.76 | CYP1A1 (0.52) | NPC1RAB9ASMN1; SMN2CYP1A1CYP1A2 | |
| SCHEMBL16217116 | 0.76 | MEN1 (0.58) | NPC1RAB9ASMN1; SMN2TP53TDP1 | |
| SCHEMBL4102560 | 0.75 | ADORA3 (0.63) | ADORA3ADORA2AADORA1CYP1A2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109202-B2 | Aminothaizoles and their use as adenosine receptor antagonists | NOVARTIS AG (CH) | 2006-09-19 | — | — | US | disclosed |
| EP-1339711-B1 | AMINOTHIAZOLES AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-07-27 | — | — | EP | disclosed |
| US-20040053982-A1 | Aminothaizoles and their use as adenosine receptor antagonists | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
| EP-1339711-A1 | AMINOTHIAZOLES AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042298-A1 | AMINOTHIAZOLES AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053982-A1 | Aminothaizoles and their use as adenosine receptor antagonists | ADORA1, ADORA3, HCAR1 | ADORA3 2/4885ADORA2A 6/4885ADORA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.